Inhibikase Therapeutics (IKT) FCF Margin (2020 - 2023)
Inhibikase Therapeutics (IKT) reported FCF Margin of 344243100.0% for Q4 2023, down 34423750523.0% year-over-year from N/an in Q4 2022, and down 6672362.53% quarter-over-quarter from 5159.16% in Q3 2023.
Inhibikase Therapeutics (IKT) FCF Margin (2020 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has 4 years of FCF Margin data on file, last reported at 344243100.0% in Q4 2023.
- FCF Margin for Q4 2023 came in at 344243100.0%, down 34423750523.0% year-over-year; the trailing twelve-month figure through Sep 2024 was 1724492300.0% (down 172448668417.0% YoY), and the FY2023 annual result was 6947.87%, up 730549.0% from the prior year.
- FCF Margin retreated to 344243100.0% in Q4 2023 per IKT's latest filing, from 5159.16% in the prior quarter.
- Over five years, FCF Margin peaked at 200.41% in Q3 2020 and troughed at 344243100.0% in Q4 2023.
- A 4-year average of 21539540.75% and a median of 4540.49% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin jumped 20509540 bps in 2022, then plunged 2000000000 bps in 2023.
- A 4-year view of FCF Margin shows it stood at 555.42% in 2020, then sank by 37833 bps to 210690.17% in 2021, then soared by 97 bps to 5594.77% in 2022, then plunged by 6152840 bps to 344243100.0% in 2023.
- Business Quant data shows IKT's FCF Margin at 344243100.0% in Q4 2023, 5159.16% in Q3 2023, and 3921.82% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -344,243,100.00% |
| Sep 30, 2023 | -5,159.16% |
| Jun 30, 2023 | -3,921.82% |
| Mar 31, 2023 | -9,256.10% |
| Dec 31, 2022 | -5,594.77% |
| Sep 30, 2022 | -78,245.73% |
| Jun 30, 2022 | -66,480.49% |
| Mar 31, 2022 | -8,546.84% |
| Dec 31, 2021 | -210,690.17% |
| Sep 30, 2021 | -615.14% |
| Jun 30, 2021 | -311.55% |
| Mar 31, 2021 | -279.58% |
| Dec 31, 2020 | -555.42% |
| Sep 30, 2020 | 200.41% |
| Jun 30, 2020 | -1.33% |
| Mar 31, 2020 | -94.33% |